SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.
Fourth Quarter and Full Year 2024 Financial Results
About Kronos Bio
Kronos Bio is a biopharmaceutical company that has historically focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. In November 2024, we announced a process to evaluate potential strategic alternatives focused on maximizing stockholder value, including, but not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, or other strategic transactions. Our activities to evaluate and pursue potential strategic alternatives may not result in any transaction or enhance stockholder value. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
| Kronos Bio, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except per share data) (Unaudited) | |||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenue | $ | 2,270 | $ | 2,286 | $ | 9,848 | $ | 6,288 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 8,409 | 18,704 | 48,664 | 84,515 | |||||||||||||
| General and administrative | 4,924 | 9,213 | 24,616 | 38,974 | |||||||||||||
| Impairment of long-lived assets and restructuring | 16,091 | 1,960 | 29,455 | 4,876 | |||||||||||||
| Total operating expenses | 29,424 | 29,877 | 102,735 | 128,365 | |||||||||||||
| Loss from operations | (27,154 | ) | (27,591 | ) | (92,887 | ) | (122,077 | ) | |||||||||
| Other income (expense), net: | |||||||||||||||||
| Interest income and other expense, net | 1,341 | 2,271 | 6,808 | 9,404 | |||||||||||||
| Total other income (expense), net | 1,341 | 2,271 | 6,808 | 9,404 | |||||||||||||
| Net loss | (25,813 | ) | (25,320 | ) | (86,079 | ) | (112,673 | ) | |||||||||
| Other comprehensive income (loss): | |||||||||||||||||
| Net unrealized gain (loss) on available-for-sale securities | (15 | ) | 274 | (10 | ) | 811 | |||||||||||
| Net comprehensive loss | $ | (25,828 | ) | $ | (25,046 | ) | $ | (86,089 | ) | $ | (111,862 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.43 | ) | $ | (0.43 | ) | $ | (1.43 | ) | $ | (1.95 | ) | |||||
| Weighted-average number of shares used to compute net loss per share, basic and diluted | 60,344 | 58,268 | 60,070 | 57,744 | |||||||||||||
| Kronos Bio, Inc. Selected Balance Sheet Data (in thousands) (Unaudited) | |||||
| December 31, 2024 | December 31, 2023 | ||||
| Cash, cash equivalents and investments | $ | 112,422 | $ | 174,986 | |
| Total assets | $ | 124,363 | $ | 213,279 | |
| Total liabilities | $ | 36,783 | $ | 54,201 | |
| Total stockholders’ equity | $ | 87,580 | $ | 159,078 | |
| Last Trade: | US$0.87 |
| Daily Volume: | 0 |
| Market Cap: | US$52.500M |
November 27, 2024 November 14, 2024 November 13, 2024 November 05, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
